Amyris, Inc., an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company delivers its products and services under the No Compromise name across various markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. It has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. and Givaudan SA. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
Previous Symbol
CUSIP03236M10
Phone510-450-0761
Debt
Debt-to-Equity RatioN/A
Current Ratio0.44
Quick Ratio0.40
Price-To-Earnings
Trailing P/E Ratio-1.43
Forward P/E Ratio-3.25
P/E GrowthN/A
Sales & Book Value
Annual Sales$143.45 million
Price / Sales2.18
Cash FlowN/A
Price / Cash FlowN/A
Book Value($4.64) per share
Price / Book-0.94
Profitability
EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-114.09%
Return on EquityN/A
Return on Assets-127.95%
Miscellaneous
Employees414
Outstanding Shares71,910,000
Market Cap$312.09 million
OptionableOptionable
Amyris (NASDAQ:AMRS) Frequently Asked Questions
What is Amyris' stock symbol?
Amyris trades on the NASDAQ under the ticker symbol "AMRS."
When did Amyris' stock split? How did Amyris' stock split work?
Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.
How were Amyris' earnings last quarter?
Amyris Inc (NASDAQ:AMRS) announced its earnings results on Tuesday, November, 13th. The biotechnology company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.96. The biotechnology company earned $14.90 million during the quarter, compared to the consensus estimate of $46.72 million. The company's quarterly revenue was down 38.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.81) earnings per share. View Amyris' Earnings History.
When is Amyris' next earnings date?
What price target have analysts set for AMRS?
2 brokers have issued twelve-month price objectives for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 118.4% from the stock's current price. View Analyst Price Targets for Amyris.
What is the consensus analysts' recommendation for Amyris?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.
What are Wall Street analysts saying about Amyris stock?
Here are some recent quotes from research analysts about Amyris stock:
- 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (11/19/2018)
- 2. HC Wainwright analysts commented, "We expect the company’s topline to grow at a five-year CAGR of 30.7% from $185.9M in 2018 to $715.6M in 2023. We expect mid- to long-term gross margins to fluctuate between 60-70%, driven by lumpiness of the high margin revenues from grants and collaboration. We are projecting operating expenses to grow at a five-year CAGR of 7.4% from 2018 to 2023. We expect the company to achieve EBITDA profitability during 2018. Based on these assumptions, we arrive at a valuation of $15.00 per share for AMRS stock." (9/28/2018)
Has Amyris been receiving favorable news coverage?
News stories about AMRS stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amyris earned a daily sentiment score of 3.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Amyris' key competitors?
Some companies that are related to Amyris include Codexis (CDXS), Renewable Energy Group (REGI), Westlake Chemical Partners (WLKP), FutureFuel (FF), Green Plains (GPRE), Green Plains Partners (GPP), REX American Resources (REX), Sino United Worldwide Consolidated (SUIC), Solarwindow Technologies (WNDW), CTD (CTDH), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS), Gevo (GEVO) and Aemetis (AMTX).
Who are Amyris' key executives?
Amyris' management team includes the folowing people:
- Mr. John G. Melo, Pres, CEO & Director (Age 52)
- Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
- Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
- Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 51)
- Dr. Joel R. Cherry, Pres of R&D (Age 57)
Who are Amyris' major shareholders?
Amyris' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (8.00%), BlackRock Inc. (3.56%), Vanguard Group Inc. (1.66%), Gilder Gagnon Howe & Co. LLC (1.54%), AWM Investment Company Inc. (1.16%) and Allianz Asset Management GmbH (0.92%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.
Which institutional investors are selling Amyris stock?
AMRS stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Engineers Gate Manager LP and Vanguard Group Inc.. Company insiders that have sold Amyris company stock in the last year include (Mauritius) Pte Ltd Maxwell, Frank Kung, John Melo and L John Doerr. View Insider Buying and Selling for Amyris.
Which institutional investors are buying Amyris stock?
AMRS stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Gilder Gagnon Howe & Co. LLC, AWM Investment Company Inc., BlackRock Inc., Northpointe Capital LLC, B. Riley Financial Inc., Allianz Asset Management GmbH and JPMorgan Chase & Co.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Kathleen Valiasek and Patrick Y Yang. View Insider Buying and Selling for Amyris.
How do I buy shares of Amyris?
Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amyris' stock price today?
One share of AMRS stock can currently be purchased for approximately $4.35.
How big of a company is Amyris?
Amyris has a market capitalization of $312.09 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.
What is Amyris' official website?
How can I contact Amyris?
Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]
MarketBeat Community Rating for Amyris (NASDAQ AMRS)
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
